Current Research on Influenza and other Respiratory Viruses: II International Symposium

Antiviral Research

Volumn 46, Issue 2, 2000, Pages 91-124

  Munoz, Flor M ^a   Galasso, George J ^b   Gwaltney Jr, Jack M ^c   Hayden, Frederick G ^c   Murphy, Brian ^d   Webster, Robert ^e   Wright, Peter ^f   Couch, Robert B ^a  

^a Baylor C ^*  (United States)

^b The Macrae Group   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; OSELTAMIVIR; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; ZANAMIVIR;

ANTIVIRAL ACTIVITY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CROSS REACTION; DRUG RESISTANCE; DRUG SAFETY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ENGINEERING; HLA SYSTEM; HUMAN; HUMAN ADENOVIRUS 2; HYPOTHESIS; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS A; MAJOR CLINICAL STUDY; PARAMYXOVIRUS; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHINOVIRUS; RISK FACTOR; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VIRUS MUTANT; WORLD HEALTH ORGANIZATION;

ADENOVIRIDAE; ANIMALIA; AVES; COXSACKIEVIRUS; DNA VIRUSES; GALLUS GALLUS; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 2; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VIRUS; MAMMALIA; PARAMYXOVIRIDAE; PHOCA; RESPIRATORY SYNCYTIAL VIRUS; RHINOVIRUS; RICE STRIPE VIRUS; RNA VIRUSES; SUS SCROFA; SYNCYTIAL VIRUS;

EID: 0034089948     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00092-9     Document Type: Article

References (50)

1. Ausejino M., Saenz A., Pham B. et al. The effectiveness of glucocorticoids in treating croup: a meta-analysis. Br. Med. J. 19:1999;595-600.
2. Belshe R.B., Gruber W.C., Mendelman O.M. et al. Efficacy of vaccination with live attenuated, cold adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136:2000;168-175.
3. Belshe R.B., Gruber W.C., Mendelman P.M. et al. Correlates of immune protection induces by live attenuated, cold adapted, trivalent intranasal influenza virus vaccine. J. Infect. Dis. 181:2000;1133-1137.
4. Belshe R.B., Mendelman P.M., Treanor J. et al. The efficacy of live attenuated, cold adapted, trivalent, intranasal influenza virus vaccine in children. New Engl. J. Med. 338:1998;1405-1412.
5. Cardosa M.J., Krishnan S., Tio P.H., Perera D., Wong S.C. Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak. Lancet. 354(9183):1999;987-991.
6. Chonmaitree T., Heikkinen T. Role of viruses in middle ear disease. Ann. NY Acad. Sci. 830:1997;143-157.
7. Colman P.M. Influenza virus neuraminidase: structure, antibodies and inhibitors. Protein Sci. 3:1994;1687-1696.
8. Couch R.B., Kasel J.A., Gerin J.L., Schulman J.L., Kilbourne E.D. Induction of partial immunity to influenza by neuraminidase-specific vaccine. J. Infect. Dis. 129:1974;411-420.
9. Cox N.J., Fukuda K. Influenza. Infect. Dis. Clin. N. Am. 12(1):1998;27-38.
10. Drinka P.J., Gravestein S., Schilling M. et al. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A, a comparison of 2 protocols. Arch. Intern. Med. 158(19):1998;2155-2159.
11. Fodor E., Devenish L., Engelhardt O.G., Palese P., Browmlee G.G., Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J. Virol. 73(11):1999;9679-9682.
12. Garcia-Sastre A., Egorov A., Matassov D. et al. Influenza A virus lacking the NS1 gene replicated in interferon-deficient systems. Virology. 252(2):1998;324-330.
13. Ghosh S., Champlin R., Couch R. et al. Rhinovirus infections in myolosuppressed adult blood and marrow transplant recipients. Clin. Infect. Dis. 29:1999;528-532.
14. Guan Y., Shortridge K.F., Krauss S., Webster R.G. Molecular characterization of H9N2 influenza viruses: Where they the donors of the 'internal' genes of H5N1 viruses in Hong Kong? Proc. Natl. Acad. Sci. 96:1999;9363-9367.
15. Gubareva L.V., Mastrosovich M.N., Brenner M.K., Bethel R.C., Webster R.G. Evidence for zanamavir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1998;1257-1262.
16. Gwaltney Jr J.M., Ruckert R.R. Rhinovirus. Richman D.D., Whitley R.J., Hayden F.G. Clinical Virology. 1997;1025-1047 Churchill Livingstone, NY.
17. Gwaltney J.M. Rhinoviruses. Evans A.S., Kaslow R.A. Viral Infection of Humans: Epidemiology and Control, 4th Ed. 1997;815-838 Plenum Press, New York.
18. Hayden, F.G., Hassman, H.A., Coats, T., Menendez, R., Bock, T., 1999. Pleconaril Treatment Shortens Duration of Picornavirus Respiratory Illness in Adults. 39th ICAAC Final Program, Abstracts and Exhibits Addendum, vol. 13 (Abst#LB-3). San Francisco, CA, 26-29 September.
19. Heikkinen T., Thint M., Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. New Engl. J. Med. 340:1999;260-264.
20. Johansson B.E., Matthews J.T., Kilbourne E.D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine. 16:1998;1009.
21. Johansson B.E., Price P.M., Kilbourne E.D. Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine. 13:1995;841-845.
22. Kaiser L., Couch R.B., Galasso G.J. et al. First international symposium on influenza and other respiratory viruses: summary and overview. Kapalua, Maui, Hawaii, December 4-6, 1998. Antivir. Res. 42:1999;149-176.
23. Karron R.A., Wright P.F., Crowe J.E. et al. Evaluation of two live, cold-passaged, temperature sensitive respiratory syncytial virus vaccines in chimpanzees, adults, infants and children. J. Infect. Dis. 176(6):1997;1428-1436.
24. Karron R.A., Wright P.F., Murphy B.R. et al. A live attenuated bovine parainfluenza type 3 virus vaccine is safe, infectious, immunogenic and phenotypically stable in healthy infants and children. J. Infect. Dis. 171(5):1995;1107-1114.
25. Karron R.A., Wright P.F., Newman F.K. et al. A live parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J. Infect. Dis. 172(6):1995;1445-1450.
26. King Jr J.C., Burke A.R., Clemens J.D. et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and non infected children. Pediatr. Infect. Dis. J. 12(9):1993;733-739.
27. Lewis V.A., Champlin R., Englund J. et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin. Infect. Dis. 23(5):1996;1033-1037.
28. Magnard C., Valette M., Aymard M., Linda B. Comparison of two nested PCR, cell culture, and antigen detection for the diagnosis of upper respiratory tract infections due to influenza viruses. J. Med. Virol. 59:1999;215-220.
29. Mendel D.B., Sidwell R.W. Influenza virus resistance to neuraminidase inhibitors. Drug Res. Updates. 1:1998;184-189.
30. Neuzil K.M., Reed G.W., Mitchell Jr E.F., Griffin M.R. Influenza-associated morbidity and mortality in young and middle-aged women. J. Am. Med. Assoc. 281:1999;901-907.
31. Nichol K.L., Mendelman P.M., Mallon K.O. et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults, a randomized controlled trial. J. Am. Med. Assoc. 282:1999;137-144.
32. Ott G., Barchfield G.L., Chernoff D., Radhakrishnan R., Van Hoogevest P., Van Nest G.A. MF59. Powell M.F., Newman M.J. Vaccine Design: the Subunit and Adjuvant Approach. 1995;277-296 Plenum Press, New York.
33. JID, 1997. Pandemic Influenza: Confronting a Re-emergent Threat. Proceedings from a meeting, Bethesda, MD, 11-13 December 1995. J. Infect. Dis., 176 (Suppl. 1), S1-90.
34. Paushinger M., Bowles N.E., Fuentes-Garcia F.J. et al. Detection of adenoviral genome in the myocardium of patients with idiopathic left ventricular dysfunction. Circulation. 99(10):1999;1348-1354.
35. Power U.F., Plotnicky-Gilquin H., Huss T. et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 230:1997;155-166.
36. Puhakka T., Makela M., Alanen A. et al. Sinusitis in common cold. J. Allergy Clin. Immunol. 101:1998b;403-408.
37. Puhakka T., Makela M., Malmstrom K. et al. Common cold: effects of intranasal fluticasone propionate treatment. J. Allergy Clin. Immunol. 101:1998a;726-731.
38. Reid M.C., Lachs M.S., Feinstein A.R. Use of methodological standards in diagnostic test research. Getting better but still not good. J. Am. Med. Assoc. 274:1995;645-651.
39. Schiff G.M., Sherwood J.R. Clinical activity of pleconaril in an experimentally induced coxsakievirus A21 respiratory infection. J. Infect. Dis. 81:2000;20-26.
40. Schilling M., Povinelli L., Krause P. et al. Efficacy of zanamavir fro chemoprophylaxis of nursing home influenza outbreaks. Vaccine. 16(18):1998;1771-1774.
41. Schowengerdt K.O., Ni J., Denfield S.W. et al. Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction. J. Heart Lung Transpl. 15(2):1996;111-123.
42. Siegrist C.A., Plotnicky-Gilquin H., Cordova M. et al. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. J. Infect. Dis. 179:1999;1326-1333.
43. Simonsen L., Clarke M.J., Williamson G.D. et al. The impact of influenza epidemics on mortality, introducing a severity index. Am. J. Public Health. 87(12):1997;1944-1950.
44. Snacken R., Kendal A.P., Haaterim L.R., Woods J.M. The next influenza pandemic: lessons from Hong Kong, 1999. Emerg. Infect. Dis. 5(2):1999;195-203.
45. Talon J., Salvatore M., O'Neill R.E. et al. Influenza A and B viruses expressing altered NS1 proteins: a novel vaccine approach. Proc. Natl. Acad. Sci. 97(8):2000;4309-4314.
46. Tasker S.A., Treanor J.J., Paxton W.B., Wallace M.R. Efficacy of influenza vaccine in HIV-infected persons. Ann. Intern. Med. 131:1999;430-433.
47. Varghese J.N., Smith P.N., Sollis S.L. et al. Drug design against a shifting target: S structural basis for resistance to inhibitors in a variant influenza virus neuraminidase. Structure. 6:1998;735-746.
48. Whimbey E., Champlin R.E., Couch R.B. et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin. Infect. Dis. 22(5):1996;778-782.
49. Whimbey E., Elting L.S., Couch R.B. et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transpl. 13(4):1994;437-440.
50. Zhou N.N., Senne D.A., Landgraf J.S. et al. Genetic reassortment of avian, swine, and human influenza A viruses in American pig. J. Virol. 73(10):1999;8851-8856.